Becton Dickinson and (BDX) Price Target Cut to $250.00 by Analysts at Piper Jaffray Companies

Becton Dickinson and (NYSE:BDX) had its target price reduced by Piper Jaffray Companies to $250.00 in a research report sent to investors on Tuesday morning, The Fly reports. They currently have an overweight rating on the medical instruments supplier’s stock. Piper Jaffray Companies also issued estimates for Becton Dickinson and’s Q1 2019 earnings at $2.79 EPS, Q2 2019 earnings at $2.90 EPS, Q3 2019 earnings at $3.07 EPS, Q4 2019 earnings at $3.33 EPS, FY2019 earnings at $12.10 EPS, Q1 2020 earnings at $3.17 EPS, Q2 2020 earnings at $3.42 EPS, Q3 2020 earnings at $3.67 EPS, Q4 2020 earnings at $3.68 EPS and FY2020 earnings at $13.94 EPS.

Other equities research analysts have also issued research reports about the stock. KeyCorp reissued a buy rating and set a $264.00 price objective on shares of Becton Dickinson and in a research note on Friday, August 3rd. Royal Bank of Canada reissued a hold rating and set a $248.00 price objective on shares of Becton Dickinson and in a research note on Friday, August 3rd. Citigroup boosted their price objective on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a buy rating in a research note on Wednesday, August 8th. Wells Fargo & Co boosted their price objective on shares of Becton Dickinson and from $275.00 to $290.00 and gave the stock an outperform rating in a research note on Thursday, September 6th. They noted that the move was a valuation call. Finally, Morgan Stanley boosted their price objective on shares of Becton Dickinson and from $250.00 to $280.00 and gave the stock an equal weight rating in a research note on Thursday, October 4th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $254.07.

Shares of BDX traded down $1.22 during trading hours on Tuesday, reaching $243.26. 1,005,699 shares of the company traded hands, compared to its average volume of 1,421,737. The firm has a market capitalization of $63.38 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 1.46 and a beta of 1.19. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95. Becton Dickinson and has a 12 month low of $209.91 and a 12 month high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.93. The firm had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The company’s revenue for the quarter was up 39.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.40 EPS. On average, research analysts forecast that Becton Dickinson and will post 12.2 EPS for the current fiscal year.

In other Becton Dickinson and news, Director Timothy M. Ring sold 42,000 shares of Becton Dickinson and stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the completion of the transaction, the director now directly owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP James C. Lim sold 5,189 shares of Becton Dickinson and stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $242.36, for a total transaction of $1,257,606.04. Following the completion of the transaction, the executive vice president now directly owns 13,318 shares of the company’s stock, valued at $3,227,750.48. The disclosure for this sale can be found here. 1.00% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of BDX. Fundsmith Equity Fund L.P. purchased a new position in shares of Becton Dickinson and during the second quarter valued at approximately $894,775,000. FMR LLC raised its holdings in shares of Becton Dickinson and by 13.7% during the second quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplier’s stock valued at $4,069,559,000 after purchasing an additional 2,049,874 shares during the last quarter. Charles Schwab Investment Advisory Inc. purchased a new position in shares of Becton Dickinson and during the second quarter valued at approximately $291,167,000. Vontobel Asset Management Inc. raised its holdings in shares of Becton Dickinson and by 823.0% during the second quarter. Vontobel Asset Management Inc. now owns 1,013,953 shares of the medical instruments supplier’s stock valued at $250,205,000 after purchasing an additional 904,097 shares during the last quarter. Finally, Cornerstone Wealth Management LLC raised its holdings in shares of Becton Dickinson and by 233.6% during the third quarter. Cornerstone Wealth Management LLC now owns 647,786 shares of the medical instruments supplier’s stock valued at $3,286,000 after purchasing an additional 453,623 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Story: What is Considered a Good Return on Equity (ROE)?

The Fly

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply